167 related articles for article (PubMed ID: 35524479)
1. Optimal Doses of Specific Antipsychotics for Relapse Prevention in a Nationwide Cohort of Patients with Schizophrenia.
Taipale H; Tanskanen A; Luykx JJ; Solmi M; Leucht S; Correll CU; Tiihonen J
Schizophr Bull; 2022 Jun; 48(4):774-784. PubMed ID: 35524479
[TBL] [Abstract][Full Text] [Related]
2. Women with Schizophrenia-Spectrum Disorders After Menopause: A Vulnerable Group for Relapse.
Sommer IE; Brand BA; Gangadin S; Tanskanen A; Tiihonen J; Taipale H
Schizophr Bull; 2023 Jan; 49(1):136-143. PubMed ID: 36198044
[TBL] [Abstract][Full Text] [Related]
3. Real-World Effectiveness of Antipsychotic Treatments in a Nationwide Cohort of 29 823 Patients With Schizophrenia.
Tiihonen J; Mittendorfer-Rutz E; Majak M; Mehtälä J; Hoti F; Jedenius E; Enkusson D; Leval A; Sermon J; Tanskanen A; Taipale H
JAMA Psychiatry; 2017 Jul; 74(7):686-693. PubMed ID: 28593216
[TBL] [Abstract][Full Text] [Related]
4. Real-world effectiveness of antipsychotic doses for relapse prevention in patients with first-episode schizophrenia in Finland: a nationwide, register-based cohort study.
Taipale H; Tanskanen A; Correll CU; Tiihonen J
Lancet Psychiatry; 2022 Apr; 9(4):271-279. PubMed ID: 35182475
[TBL] [Abstract][Full Text] [Related]
5. Antipsychotics Use Is Associated With Greater Adherence to Cardiometabolic Medications in Patients With Schizophrenia: Results From a Nationwide, Within-subject Design Study.
Solmi M; Tiihonen J; Lähteenvuo M; Tanskanen A; Correll CU; Taipale H
Schizophr Bull; 2022 Jan; 48(1):166-175. PubMed ID: 34286338
[TBL] [Abstract][Full Text] [Related]
6. Comparative Effectiveness of Antipsychotic Drugs for Rehospitalization in Schizophrenia-A Nationwide Study With 20-Year Follow-up.
Taipale H; Mehtälä J; Tanskanen A; Tiihonen J
Schizophr Bull; 2018 Oct; 44(6):1381-1387. PubMed ID: 29272458
[TBL] [Abstract][Full Text] [Related]
7. [Cost-effectiveness analysis of schizophrenic patient care settings: impact of an atypical antipsychotic under long-acting injection formulation].
Llorca PM; Miadi-Fargier H; Lançon C; Jasso Mosqueda G; Casadebaig F; Philippe A; Guillon P; Mehnert A; Omnès LF; Chicoye A; Durand-Zaleski I
Encephale; 2005; 31(2):235-46. PubMed ID: 15959450
[TBL] [Abstract][Full Text] [Related]
8. Comparative effectiveness of risperidone long-acting injectable vs first-generation antipsychotic long-acting injectables in schizophrenia: results from a nationwide, retrospective inception cohort study.
Nielsen J; Jensen SO; Friis RB; Valentin JB; Correll CU
Schizophr Bull; 2015 May; 41(3):627-36. PubMed ID: 25180312
[TBL] [Abstract][Full Text] [Related]
9. Letter to the Editor: Rethinking The Cost Of Antipsychotic Treatment: The Average Cost Of The Drugs Used In Turkey In 2020.
Yıldız M; Osman E
Turk Psikiyatri Derg; 2022; 33(2):146-148. PubMed ID: 35730516
[TBL] [Abstract][Full Text] [Related]
10. Real-world Effectiveness of Pharmacologic Treatments for the Prevention of Rehospitalization in a Finnish Nationwide Cohort of Patients With Bipolar Disorder.
Lähteenvuo M; Tanskanen A; Taipale H; Hoti F; Vattulainen P; Vieta E; Tiihonen J
JAMA Psychiatry; 2018 Apr; 75(4):347-355. PubMed ID: 29490359
[TBL] [Abstract][Full Text] [Related]
11. Cost Effectiveness of Paliperidone Long-Acting Injectable Versus Other Antipsychotics for the Maintenance Treatment of Schizophrenia in France.
Druais S; Doutriaux A; Cognet M; Godet A; Lançon C; Levy P; Samalin L; Guillon P
Pharmacoeconomics; 2016 Apr; 34(4):363-91. PubMed ID: 26883132
[TBL] [Abstract][Full Text] [Related]
12. Atypical antipsychotics for psychosis in adolescents.
Kumar A; Datta SS; Wright SD; Furtado VA; Russell PS
Cochrane Database Syst Rev; 2013 Oct; (10):CD009582. PubMed ID: 24129841
[TBL] [Abstract][Full Text] [Related]
13. A nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophrenia.
Tiihonen J; Haukka J; Taylor M; Haddad PM; Patel MX; Korhonen P
Am J Psychiatry; 2011 Jun; 168(6):603-9. PubMed ID: 21362741
[TBL] [Abstract][Full Text] [Related]
14. [Comparison of medical and economic benefits of antipsychotics in the treatment of schizophrenia in France].
Druais S; Doutriaux A; Cognet M; Godet A; Lançon C; Levy P; Samalin L; Guillon P
Encephale; 2017 Aug; 43(4):311-320. PubMed ID: 27623123
[TBL] [Abstract][Full Text] [Related]
15. Safety of Antipsychotic Polypharmacy Versus Monotherapy in a Nationwide Cohort of 61,889 Patients With Schizophrenia.
Taipale H; Tanskanen A; Tiihonen J
Am J Psychiatry; 2023 May; 180(5):377-385. PubMed ID: 36945825
[TBL] [Abstract][Full Text] [Related]
16. Switching patients with stable schizophrenia or schizoaffective disorder from olanzapine to risperidone long-acting injectable.
Rosa F; Schreiner A; Thomas P; Sherif T
Clin Drug Investig; 2012 Apr; 32(4):267-79. PubMed ID: 22339430
[TBL] [Abstract][Full Text] [Related]
17. Dose-Response Meta-Analysis of Antipsychotic Drugs for Acute Schizophrenia.
Leucht S; Crippa A; Siafis S; Patel MX; Orsini N; Davis JM
Am J Psychiatry; 2020 Apr; 177(4):342-353. PubMed ID: 31838873
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness of Antipsychotic Use for Reducing Risk of Work Disability: Results From a Within-Subject Analysis of a Swedish National Cohort of 21,551 Patients With First-Episode Nonaffective Psychosis.
Solmi M; Taipale H; Holm M; Tanskanen A; Mittendorfer-Rutz E; Correll CU; Tiihonen J
Am J Psychiatry; 2022 Dec; 179(12):938-946. PubMed ID: 36200276
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness model of long-acting risperidone in schizophrenia in the US.
Edwards NC; Rupnow MF; Pashos CL; Botteman MF; Diamond RJ
Pharmacoeconomics; 2005; 23(3):299-314. PubMed ID: 15836010
[TBL] [Abstract][Full Text] [Related]
20. [Long acting injectable antipsychotics in the treatment of schizophrenia: a review of literature].
Graffino M; Montemagni C; Mingrone C; Rocca P
Riv Psichiatr; 2014; 49(3):115-23. PubMed ID: 25000887
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]